Ongoing Anticancer Agents
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 December 2025 | Viewed by 1665
Special Issue Editor
Interests: anticancer drugs; phenotypic drug discovery; tumor cell biology; tumor microenvironment; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tumorigenesis, arguably the most intricate pathological process, arises from the progressive accumulation of genetic mutations over extended periods, ultimately leading to the gradual disruption of homeostatic mechanisms at the cellular, tissue, and organismal levels. Over recent decades, advances in understanding the molecular and cellular mechanisms underlying tumorigenesis have significantly influenced the development of anticancer therapies. Remarkably, since the early 2000s, the number of anticancer drugs approved for clinical application has increased from a few dozen to several hundred distinct agents.
In the effort to target the hallmarks of cancer—that is, the specific functional characteristics enabling cancer cells to survive, proliferate, and metastasize—numerous classes of anticancer drugs are currently undergoing rigorous investigation and development. This IJMS Special Issue, entitled Ongoing Anticancer Agents, aims to compile both experimental studies and review articles that reflect the complexity of the disease and highlight various aspects of the foundational research focused on therapeutic innovation.
Dr. Mauro Coluccia
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumorigenesis
- anticancer drugs
- therapeutic innovation
- platinum-based drugs
- anticancer therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
